Selling price and price change trend of adagrasib (Krazati) targeted drug in domestic and foreign markets

Adagrasiib (Krazati) is an oral targeted drug mainly used to treat patients with KRAS G12C mutation-positive non-small cell lung cancer. It specifically inhibits the activity of KRAS G12C mutant protein and blocks downstream signaling pathways, thereby inhibiting tumor cell proliferation and survival. As a new type of precision targeted therapy drug, adagrasib has not yet been officially launched in China. Patients cannot directly obtain the drug locally and need to rely on overseas channels to purchase it.

In overseas markets, the original drug of adagrasib is mainly the American version, which is extremely expensive, with each box selling for hundreds of thousands of yuan. The high price reflects factors such as the research and development costs of the original drug, production process, and market pricing, which puts a very heavy financial burden on ordinary patients or long-term treatment recipients, so it is subject to certain restrictions in actual use.

In contrast, foreign generic drugs provide patients with more affordable options. For example, the price of generic adagrasibu on the Laos market is about more than 3,000 yuan per box, and the drug ingredients are basically the same as the original drug, so it can be used as a substitute for the original drug to a certain extent. The launch of generic drugs and the downward trend in prices have provided patients with economically feasible long-term medication options, while also promoting the gradual stabilization of market prices.
When choosing drug purchasing channels, patients should give priority to the formality and safety of drugs and avoid quality risks caused by purchasing through informal channels. Obtaining adagrasib through regular overseas pharmacies or compliant cross-border medical platforms not only ensures the quality and consistency of the ingredients, but also provides complete medication guidance. Reasonable selection of original drugs or generic drugs under the guidance of doctors can ensure affordability while ensuring efficacy, and achieve safer and more controllable treatment management.
Reference link: https://www.drugs.com